ImmunoPrecise Antibodies (NASDAQ:IPA – Get Rating)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They currently have a $9.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 171.90% from the stock’s previous close.
ImmunoPrecise Antibodies Stock Down 1.8 %
IPA opened at $3.31 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.10 and a quick ratio of 2.89. The business has a 50 day simple moving average of $4.33 and a 200-day simple moving average of $4.78. The stock has a market capitalization of $82.52 million, a P/E ratio of -3.85 and a beta of 0.60. ImmunoPrecise Antibodies has a 12 month low of $3.17 and a 12 month high of $6.50.
ImmunoPrecise Antibodies (NASDAQ:IPA – Get Rating) last posted its quarterly earnings results on Thursday, December 15th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.09). The business had revenue of $3.89 million during the quarter, compared to analyst estimates of $3.91 million. ImmunoPrecise Antibodies had a negative net margin of 126.00% and a negative return on equity of 39.89%. On average, equities analysts anticipate that ImmunoPrecise Antibodies will post -0.71 earnings per share for the current fiscal year.
Hedge Funds Weigh In On ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Company Profile
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes.
- Get a free copy of the StockNews.com research report on ImmunoPrecise Antibodies (IPA)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.